Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–8 of 8 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: High-risk Lung Nodules Clear all
Terminated No phase listed Observational

Circulating Tumor DNA in Patients at High Risk for Lung Cancer

NCT02715102
View directory record Official record
Conditions
Cancer of the Lung, Lung Cancer, Lung Neoplasms, Adenocarcinoma of the Lung, Non Small Cell Carcinoma of the Lung, Small Cell Carcinoma of the Lung
Interventions
Not listed
Lead sponsor
Pathway Genomics
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2017 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Phase 2 Interventional Results available

Acetylsalicylic Acid Compared to Placebo in Treating High-Risk Patients With Subsolid Lung Nodules

NCT02169271
View directory record Official record
Conditions
Current Smoker, Former Smoker, Multiple Pulmonary Nodules, Tobacco Use Disorder
Interventions
Aspirin, Laboratory Biomarker Analysis, Placebo
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
50 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Jul 22, 2026, 10:41 AM EDT
Recruiting Not applicable Interventional

Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.

NCT07168993
View directory record Official record
Conditions
Lung Cancer (Diagnosis)
Interventions
Standard medical treatment
Other
Lead sponsor
bioAffinity Technologies Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
2,063 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
11
States / cities
Palo Alto, California • Grand Junction, Colorado • Bay Pines, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study

NCT03634241
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8
Interventions
Pembrolizumab, Quality-of-Life Assessment, Computed Tomography, Biospecimen Collection
Biological · Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Jul 22, 2026, 10:41 AM EDT
Recruiting Phase 2 Interventional

Immunoprevention for High-risk Lung Lesions

NCT07284485
View directory record Official record
Conditions
High-risk Lung Nodules
Interventions
Nadunolimab
Biological
Lead sponsor
Robert Samstein
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jul 22, 2026, 10:41 AM EDT
Active, not recruiting No phase listed Observational

DECAMP 1 PLUS: Prediction of Lung Cancer Using Noninvasive Biomarkers

NCT04165564
View directory record Official record
Conditions
Pulmonary Disease
Interventions
Institutional standard of care, Biosamples of airway and blood
Other
Lead sponsor
Boston University
Other
Eligibility
46 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jul 22, 2026, 10:41 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Retrospective Clinical Trial Comparing Radiologists' Diagnosis Accuracy in Lung Cancer Screening Population With and Without the Help of an AI/ML Tech-based SaMD

NCT06751576
View directory record Official record
Conditions
High Risk Cancer, Lung Cancer
Interventions
Median LCS
Device
Lead sponsor
Median Technologies
Industry
Eligibility
50 Years to 80 Years
Enrollment
480 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • Memphis, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced Jul 22, 2026, 10:41 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Standalone Observational Study Assessing the Performance of an AI/ML Tech-based SaMD on Chest LDCT Images (REALITY)

NCT06576232
View directory record Official record
Conditions
High Risk Cancer
Interventions
Median LCS
Device
Lead sponsor
Median Technologies
Industry
Eligibility
50 Years to 80 Years
Enrollment
1,147 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • Memphis, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Jul 22, 2026, 10:41 AM EDT